Terms: = Leukemia AND U2AF1, ENSG00000160201, 7307, Q01081, U2AFBP, U2AF35, RNU2AF1, RN, FP793, DKFZp313J1712 AND Treatment
49 results:
1. Mutant u2af1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid leukemia.
Jin P; Wang X; Jin Q; Zhang Y; Shen J; Jiang G; Zhu H; Zhao M; Wang D; Li Z; Zhou Y; Li W; Zhang W; Liu Y; Wang S; Jin W; Cao Y; Sheng G; Dong F; Wu S; Li X; Jin Z; He M; Liu X; Chen L; Zhang Y; Wang K; Li J
Cancer Res; 2024 May; 84(10):1583-1596. PubMed ID: 38417135
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of u2af1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract] [Full Text] [Related]
3. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD; Iqbal M; Von Roemeling R; Von Roemeling C; Tun HW
Front Immunol; 2023; 14():1239082. PubMed ID: 37954584
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
5. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
Bonnet S; Carillo S; Legrand B; Burroni B; Lavabre-Bertrand T; Requirand G; Robert N; Fornero L; Al Mansoori A; Moreaux J; Cartron G; Gabellier L; Herbaux C
Eur J Haematol; 2024 Mar; 112(3):475-478. PubMed ID: 37918825
[TBL] [Abstract] [Full Text] [Related]
6. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract] [Full Text] [Related]
7. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract] [Full Text] [Related]
8. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink JR; van Zeventer IA; Chitu DA; Pabst T; Klein SK; Stussi G; Griskevicius L; Valk PJM; Cloos J; van de Loosdrecht AA; Breems D; van Lammeren-Venema D; Boersma R; Jongen-Lavrencic M; Fehr M; Hoogendoorn M; Manz MG; Söhne M; van Marwijk Kooy R; Deeren D; van der Poel MWM; Legdeur MC; Tick L; Chalandon Y; Ammatuna E; Blum S; Löwenberg B; Ossenkoppele GJ; ; ; Huls G
Blood Cancer J; 2023 Jun; 13(1):93. PubMed ID: 37336890
[TBL] [Abstract] [Full Text] [Related]
9. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
10. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
González-Gil C; Morgades M; Lopes T; Fuster-Tormo F; García-Chica J; Zhao R; Montesinos P; Torrent A; Diaz-Beya M; Coll R; Hermosín L; Mercadal S; González-Campos J; Zamora L; Artola T; Vall-Llovera F; Tormo M; Gil-Cortés C; Barba P; Novo A; Ribera J; Bernal T; De Ugarriza PL; Queipo MP; Martínez-Sánchez P; Giménez A; González-Martínez T; Cladera A; Cervera J; Fernández-Martín R; Ardaiz MÁ; Vidal MJ; Baena Á; López-Bigas N; Bigas A; Maciejewski J; Orfao A; Ribera JM; Genescà E
Haematologica; 2023 Apr; 108(4):969-980. PubMed ID: 36325893
[TBL] [Abstract] [Full Text] [Related]
11. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H
Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121
[TBL] [Abstract] [Full Text] [Related]
12. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.
Eckardt JN; Röllig C; Metzeler K; Kramer M; Stasik S; Georgi JA; Heisig P; Spiekermann K; Krug U; Braess J; Görlich D; Sauerland CM; Woermann B; Herold T; Berdel WE; Hiddemann W; Kroschinsky F; Schetelig J; Platzbecker U; Müller-Tidow C; Sauer T; Serve H; Baldus C; Schäfer-Eckart K; Kaufmann M; Krause S; Hänel M; Schliemann C; Hanoun M; Thiede C; Bornhäuser M; Wendt K; Middeke JM
Haematologica; 2023 Mar; 108(3):690-704. PubMed ID: 35708137
[TBL] [Abstract] [Full Text] [Related]
13. Advances in the treatment of Hairy Cell leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract] [Full Text] [Related]
14. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract] [Full Text] [Related]
15. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
16. Bilineal evolution of a u2af1-mutated clone associated with acquisition of distinct secondary mutations.
Montgomery ND; Galeotti J; Johnson SM; Commander L; Weimer ET; Chandra PK; Nazir T; Alexander TB; Zeidner JF; Foster MC
Blood Adv; 2021 Dec; 5(24):5612-5616. PubMed ID: 34581783
[TBL] [Abstract] [Full Text] [Related]
17. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract] [Full Text] [Related]
18. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
[TBL] [Abstract] [Full Text] [Related]
19. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract] [Full Text] [Related]
20. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract] [Full Text] [Related]
[Next]
